Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Nafamostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 9/20 | 0.64 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.58 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.58 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.58 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.64 |
| ▸ | KLK1 | P06870 | 3/20 | 0.64 |
| ▸ | F10 | P00742 | 3/20 | 0.64 |
| ▸ | C1R | P00736 | 2/20 | 0.64 |
| ▸ | PLG | P00747 | 10/20 | 0.58 |
| ▸ | F12 | P00748 | 6/20 | 0.58 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL564665 | 1.00 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29832433 | 1.00 | FTO (0.70) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL874941 | 0.95 | FTO (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL135503 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29429445 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL16069975 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL29429443 | 0.94 | PRSS1 (0.64) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL3302794 | 0.93 | PRSS1 (0.63) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL7345508 | 0.91 | PRSS1 (0.62) | FTOPRSS1F2KLKB1KLK1 | |
| Nafamostat SCHEMBL7338487 | 0.90 | FTO (0.58) | FTOPRSS1F2KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375413-A1 | METHOD OF INHIBITING LIPASE ACTIVITY IN AGING | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | claimed |
| US-20250262230-A1 | HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-21 | — | — | US | claimed |
| EP-4543459-A1 | HMGB1 INHIBITORS FOR TREATMENT OF APOE4-RELATED TAUOPATHIES INCLUDING ALZHEIMER'S DISEASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2025-04-30 | — | — | EP | claimed |
| WO-2024124212-A1 | DEVICES AND METHODS FOR DETECTION OF DISEASE BIOMARKERS AND THERAPEUTIC EFFECTIVENESS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2023250249-A1 | HMGB1 INHIBITORS FOR TREATMENT OF APOE4-RELATED TAUOPATHIES INCLUDING ALZHEIMER'S DISEASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2023-12-28 | — | — | WO | claimed |
| CN-115192537-A | Nafamostat mesylate composition and preparation method thereof | 康普药业股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-110330447-B | Preparation method and application of nafamostat mesylate intermediate | 北京赛升药业股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| WO-2022065860-A1 | INHALABLE FORMULATION COMPRISING NAFAMOSTAT OR CAMOSTAT | 충북대학교 산학협력단 | 2022-03-31 | — | — | WO | claimed |
| US-20220034903-A1 | Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-03 | — | — | US | claimed |
| US-20030190368-A1 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-09 | — | — | US | claimed |
| US-6534283-B1 | Method for treatment and prevention of physiological shock | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-03-18 | — | — | US | claimed |
| US-6297024-B1 | SAMPLING MAMMALIAN PLASMA HAVING METAL ION CHELATOR OR AGENT THAT BINDS OR REMOVES CALCIUM IONS, THEN MEASURING KINETICS OF IN VITRO COMPLEMENT ACTIVATION AS FUNCTION OF TIME OR AMOUNT OF IN VITRO COMPLEMENT ACTIVATION, AND CORRELATING | CELL ACTIVATION, INC. | 2001-10-02 | — | — | US | claimed |
| EP-1121458-A1 | METHODS FOR ASSESSING COMPLEMENT ACTIVATION | Cell Activation, Inc. (US) | 2001-08-08 | — | — | EP | claimed |
| EP-1062323-A2 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | Cell Activation, Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| WO-2000022160-A9 | METHODS FOR ASSESSING COMPLEMENT ACTIVATION | CELL ACTIVATION INC (US) | 2000-08-24 | — | — | WO | claimed |
| WO-2000022160-A1 | METHODS FOR ASSESSING COMPLEMENT ACTIVATION | CELL ACTIVATION, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999046367-A2 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | CELL ACTIVATION, INC. (US) | 1999-09-16 | — | — | WO | claimed |
| JP-5246891-A | — | — | None | — | — | JP | disclosed |
| US-4454338-A | 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE | TORII & CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262230-A1 | HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease | HMGB1, HMGB2, HMGB3 | F2 4211/4885CHRM1 3161/4885DRD2 4795/4885 |
| US-20030190368-A1 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | SERPINB1, PLAT, SERPINE1 | F2 37/4885CHRM1 3989/4885DRD2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.